BCL2L11 and chronic myelogenous leukemia, BCR-ABL1 positive: Notably, the Hsp70-Bim PPI has been identified as an anti-CML target, and S1g-2 exhibits potent activity against Bcr-Abl-independent TKI resistance [12].